University of Minnesota. Driven to Discover.
Four research teams from India receive awards for point-of-care diagnostic tests, 3 of them focused on sepsis.
A review finds the biomarker cut mortality and antibiotic exposure in patients with acute respiratory infections.
Recommendations focus on public-private R&D funding, incentives, and other steps.
The fast, automated assay performs well against gold standard TB tests.
Point-of-care tests, shared decision making, and procalcitonin-guided therapy were singled out.
Funds will help combat resistance, launch a TB surveillance center.
The results suggest that clinical labs should consider using an additional test to validate results.
Two companies that have received funds—Spero Therapeutics and Entasis Therapeutics—say CARB-X support has been instrumental.
"If we can eradicate the empirical use of antibiotics . . . we can achieve a lot," Zowawi says.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.